|
US2020283396A1
|
|
Caspase inhibitors and methods of use thereof
|
|
EP3397251A1
|
|
Methods of using caspase inhibitors in treatment of liver disease
|
|
US2017128519A1
|
|
Caspase inhibitors for the treatment of colorectal cancer
|
|
WO2017079566A1
|
|
Caspase inhibitors for use in the treatment of liver cancer
|
|
SG11201609256SA
|
|
Treatment of the complications of chronic liver disease with caspase inhibitors
|
|
WO2008106167A1
|
|
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
WO2008106166A2
|
|
Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
|
|
CN101668520A
|
|
Methods for the treatment of liver diseases
|
